Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 2Recurrence 1Primary Myelofibrosis 1Myelodysplastic-Myeloproliferative Diseases 1Anemia 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × ACE-011 × Clear all
NCT01562405 2026-01-14

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 1 Active not recruiting
33 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01712308 2023-10-10

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

M.D. Anderson Cancer Center

Phase 2 Completed
56 enrolled 9 charts
Classical hematologyMyeloid

Anemia, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT02230917 2016-09-01

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Indiana University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡